$BHC
Bausch Health Companies Inc. Stock $bhc

$bhc Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-Q Financial Statement

#000088559024000036 Filed on October 31, 2024

Income Statement

Concept	2024 Q4	2024 Q3
Revenue		$2.510B
YoY Change		12.15%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin		$850.0M
YoY Change		18.88%
% of Gross Profit
Research & Development		$146.0M
YoY Change		-4.58%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses		$996.0M
YoY Change		14.75%
Operating Profit		$318.0M
YoY Change		2171.43%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net		-$225.0M
YoY Change		275.0%
Pretax Income		-$21.00M
YoY Change		-93.56%
Income Tax		$71.00M
% Of Pretax Income
Net Earnings		-$85.00M
YoY Change		-77.51%
Net Earnings / Revenue		-3.39%
Basic Earnings Per Share		-$0.23
Diluted Earnings Per Share		-$0.23
COMMON SHARES
Basic Shares Outstanding	367.8M shares	367.1M shares
Diluted Shares Outstanding		368.4M shares

Balance Sheet

Concept	2024 Q4	2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents		$719.0M
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory		$1.655B
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets		$5.351B
YoY Change		6.0%
LONG-TERM ASSETS
Property, Plant & Equipment		$1.789B
YoY Change		12.94%
Goodwill		$11.17B
YoY Change		-0.14%
Intangibles		$5.652B
YoY Change		-15.99%
Long-Term Investments
YoY Change
Other Assets		$389.0M
YoY Change		18.6%
Total Long-Term Assets		$21.19B
YoY Change		-3.76%
TOTAL ASSETS
Total Short-Term Assets		$5.351B
Total Long-Term Assets		$21.19B
Total Assets		$26.54B
YoY Change		-1.94%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable		$667.0M
YoY Change		17.22%
Accrued Expenses		$3.386B
YoY Change		8.56%
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due		$453.0M
YoY Change		-15.49%
Total Short-Term Liabilities		$4.506B
YoY Change		6.68%
LONG-TERM LIABILITIES
Long-Term Debt		$21.05B
YoY Change		-3.84%
Other Long-Term Liabilities		$805.0M
YoY Change		11.65%
Total Long-Term Liabilities		$21.86B
YoY Change		-3.34%
TOTAL LIABILITIES
Total Short-Term Liabilities		$4.506B
Total Long-Term Liabilities		$21.86B
Total Liabilities		$26.78B
YoY Change		-1.89%
SHAREHOLDERS EQUITY
Retained Earnings		-$9.917B
YoY Change		1.83%
Common Stock		$10.69B
YoY Change		0.75%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity		-$1.174B
YoY Change
Total Liabilities & Shareholders Equity		$26.54B
YoY Change		-1.94%

Cashflow Statement

Concept	2024 Q4	2024 Q3
OPERATING ACTIVITIES
Net Income		-$85.00M
YoY Change		-77.51%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities
Cash From Investing Activities
Cash From Financing Activities
Net Change In Cash
YoY Change
FREE CASH FLOW
Cash From Operating Activities
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	H7L 4A8
	dei	Entity Central Index Key EntityCentralIndexKey	0000885590
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-14956
	dei	Entity Registrant Name EntityRegistrantName	Bausch Health Companies Inc.
	dei	Entity Address Country EntityAddressCountry	CA
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-0448205
	dei	Entity Address Address Line1 EntityAddressAddressLine1	2150 St. Elzéar Blvd. West
	dei	Entity Address City Or Town EntityAddressCityOrTown	Laval
	dei	Security12b Title Security12bTitle	Common Shares, No Par Value
	dei	Trading Symbol TradingSymbol	BHC
	dei	Security Exchange Name SecurityExchangeName	NYSE
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	367803401	shares
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	719000000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	947000000	usd
CY2024Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent	31000000	usd
CY2023Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	15000000	usd
CY2024Q3	us-gaap	Receivables Net Current ReceivablesNetCurrent	2094000000	usd
CY2023Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	1998000000	usd
CY2024Q3	us-gaap	Inventory Net InventoryNet	1655000000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	1544000000	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	852000000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1092000000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1789000000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1707000000	usd
CY2024Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	5652000000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	6456000000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	11183000000	usd
CY2024Q3	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	2188000000	usd
CY2023Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	2101000000	usd
CY2024Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	389000000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	307000000	usd
CY2023Q4	us-gaap	Assets Assets	27350000000	usd
CY2024Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	667000000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	719000000	usd
CY2024Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3386000000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3133000000	usd
CY2024Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	453000000	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	450000000	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	4506000000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4302000000	usd
CY2024Q3	bhc	Business Combination Contingent Consideration Noncurrent Liability BusinessCombinationContingentConsiderationNoncurrentLiability	248000000	usd
CY2023Q4	bhc	Business Combination Contingent Consideration Noncurrent Liability BusinessCombinationContingentConsiderationNoncurrentLiability	253000000	usd
CY2024Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	21054000000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	21938000000	usd
CY2024Q3	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	169000000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	163000000	usd
CY2024Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	805000000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	776000000	usd
CY2024Q3	us-gaap	Liabilities Liabilities	26782000000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	27432000000	usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	367695267	shares
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	367695267	shares
CY2024Q3	us-gaap	Minority Interest MinorityInterest	932000000	usd
CY2023Q4	us-gaap	Minority Interest MinorityInterest	940000000	usd
CY2024Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-242000000	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-82000000	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	26540000000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	27350000000	usd
CY2024Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2510000000	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2238000000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7066000000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	6349000000	usd
CY2024Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	850000000	usd
CY2023Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	715000000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2476000000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2151000000	usd
CY2024Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	146000000	usd
CY2023Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	153000000	usd
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	453000000	usd
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	452000000	usd
CY2024Q3	bhc	Amortization Of Intangible Assets Excluding Amortization Allocated To Revenues Cost Of Good Sold AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold	274000000	usd
CY2023Q3	bhc	Amortization Of Intangible Assets Excluding Amortization Allocated To Revenues Cost Of Good Sold AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold	253000000	usd
	bhc	Amortization Of Intangible Assets Excluding Amortization Allocated To Revenues Cost Of Good Sold AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold	818000000	usd
	bhc	Amortization Of Intangible Assets Excluding Amortization Allocated To Revenues Cost Of Good Sold AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold	795000000	usd
CY2024Q3	bhc	Goodwill Impairment Loss Not Included In Asset Impairment Charges GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges	0	usd
CY2023Q3	bhc	Goodwill Impairment Loss Not Included In Asset Impairment Charges GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges	402000000	usd
	bhc	Goodwill Impairment Loss Not Included In Asset Impairment Charges GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges	0	usd
	bhc	Goodwill Impairment Loss Not Included In Asset Impairment Charges GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges	402000000	usd
CY2023Q3	us-gaap	Asset Impairment Charges AssetImpairmentCharges	4000000	usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	6000000	usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	54000000	usd
CY2024Q3	bhc	Restructuring Charges And Initial Public Offering Costs RestructuringChargesAndInitialPublicOfferingCosts	1000000	usd
CY2023Q3	bhc	Restructuring Charges And Initial Public Offering Costs RestructuringChargesAndInitialPublicOfferingCosts	14000000	usd
	bhc	Restructuring Charges And Initial Public Offering Costs RestructuringChargesAndInitialPublicOfferingCosts	25000000	usd
	bhc	Restructuring Charges And Initial Public Offering Costs RestructuringChargesAndInitialPublicOfferingCosts	40000000	usd
CY2024Q3	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-225000000	usd
CY2023Q3	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-60000000	usd
	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-245000000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-42000000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-383000000	usd
CY2024Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	71000000	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	56000000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	128000000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	181000000	usd
CY2024Q3	us-gaap	Profit Loss ProfitLoss	-92000000	usd
CY2023Q3	us-gaap	Profit Loss ProfitLoss	-382000000	usd
	us-gaap	Profit Loss ProfitLoss	-170000000	usd
	us-gaap	Profit Loss ProfitLoss	-564000000	usd
CY2024Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-7000000	usd
CY2023Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-4000000	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-31000000	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-11000000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-85000000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-378000000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-139000000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-553000000	usd
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.23
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.03
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.38
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.52
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	368400000	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	365400000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	367700000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	364500000	shares
CY2024Q3	us-gaap	Profit Loss ProfitLoss	-92000000	usd
	us-gaap	Profit Loss ProfitLoss	-170000000	usd
	us-gaap	Profit Loss ProfitLoss	-564000000	usd
CY2024Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	54000000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-134000000	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-64000000	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	0	usd
CY2023Q3	us-gaap	Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent	2000000	usd
	us-gaap	Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent	0	usd
	us-gaap	Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent	2000000	usd
CY2024Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	54000000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-64000000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-2000000	usd
CY2024Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-38000000	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-518000000	usd
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-234000000	usd
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-566000000	usd
CY2024Q3	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-13000000	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	9000000	usd
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-29000000	usd
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-18000000	usd
CY2024Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-25000000	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-527000000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-205000000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-548000000	usd
CY2024Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-227000000	usd
CY2024Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	0	usd
CY2024Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	38000000	usd
CY2024Q3	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	5000000	usd
CY2024Q3	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	0	usd
	dei	Local Phone Number LocalPhoneNumber	744-6792
CY2024Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	10489000000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	10423000000	usd
CY2024Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	201000000	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	214000000	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-9917000000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-9778000000	usd
CY2024Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1947000000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1881000000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	-1174000000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-1022000000	usd
CY2024Q3	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	0	usd
CY2024Q3	us-gaap	Costs And Expenses CostsAndExpenses	2192000000	usd
CY2023Q3	us-gaap	Costs And Expenses CostsAndExpenses	2224000000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	6078000000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	5748000000	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	318000000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	14000000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	988000000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	601000000	usd
CY2024Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	7000000	usd
CY2023Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	6000000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	24000000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	19000000	usd
CY2024Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	346000000	usd
CY2023Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	339000000	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	1051000000	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	965000000	usd
CY2024Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2023Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	23000000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2024Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	0	usd
CY2023Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-7000000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-26000000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-38000000	usd
CY2024Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-21000000	usd
CY2023Q3	us-gaap	Profit Loss ProfitLoss	-382000000	usd
CY2024Q3	us-gaap	Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent	0	usd
CY2024Q3	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	10000000	usd
CY2024Q3	us-gaap	Profit Loss ProfitLoss	-92000000	usd
CY2024Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	54000000	usd
CY2024Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-242000000	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	271000000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	29000000	usd
CY2023Q3	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	8000000	usd
	bhc	Derivative Gain Excluded Component DerivativeGainExcludedComponent	10000000	usd
	bhc	Derivative Gain Excluded Component DerivativeGainExcludedComponent	10000000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	23000000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
	bhc	Payment For Debt Extinguishment Or Debt Prepayment Cost Operating Activities PaymentForDebtExtinguishmentOrDebtPrepaymentCostOperatingActivities	0	usd
	bhc	Payment For Debt Extinguishment Or Debt Prepayment Cost Operating Activities PaymentForDebtExtinguishmentOrDebtPrepaymentCostOperatingActivities	2000000	usd
	bhc	Payment For Contingent Consideration Liability Including Accretion Operating Activities PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities	7000000	usd
	bhc	Payment For Contingent Consideration Liability Including Accretion Operating Activities PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities	4000000	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	23000000	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	23000000	usd
	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	20000000	usd
	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	17000000	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	7000000	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	36000000	usd
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-9000000	usd
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-8000000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-953000000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1554000000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-1000000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-10000000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	189000000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	962000000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	591000000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	750000000	usd
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	719000000	usd
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	760000000	usd
CY2023Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent	20000000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	750000000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	780000000	usd
CY2024Q3	us-gaap	Number Of Countries In Which Entity Operates NumberOfCountriesInWhichEntityOperates	90	country
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	3000000	usd
	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	3000000	usd
	us-gaap	Allowance For Doubtful Accounts Receivable Recoveries AllowanceForDoubtfulAccountsReceivableRecoveries	3000000	usd
	bhc	Accounts Receivable Allowance For Foreign Exchange And Other AccountsReceivableAllowanceForForeignExchangeAndOther	3000000	usd
CY2023Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	33000000	usd
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	368400000	shares
	us-gaap	Profit Loss ProfitLoss	-170000000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	780000000	usd
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	A1
	dei	Entity Address State Or Province EntityAddressStateOrProvince	QC
	dei	Entity Address Country EntityAddressCountry	CA
	dei	City Area Code CityAreaCode	514
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024Q3	us-gaap	Goodwill Goodwill	11171000000	usd
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.03
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	365400000	shares
CY2024Q3	us-gaap	Assets Current AssetsCurrent	5351000000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	5596000000	usd
CY2024Q3	us-gaap	Assets Assets	26540000000	usd
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	365238917	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	365238917	shares
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-326000000	usd
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.23
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.38
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.52
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	367700000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	364500000	shares
CY2023Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-136000000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	0	usd
CY2023Q3	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	0	usd
CY2023Q3	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	9000000	usd
CY2023Q3	us-gaap	Profit Loss ProfitLoss	-382000000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-136000000	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-235000000	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-82000000	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	0	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	107000000	usd
	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	23000000	usd
	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	0	usd
	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	10000000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-64000000	usd
CY2024Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-242000000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	260000000	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	0	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	103000000	usd
	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	23000000	usd
	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	0	usd
	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	9000000	usd
	us-gaap	Profit Loss ProfitLoss	-564000000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-2000000	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-235000000	usd
	us-gaap	Profit Loss ProfitLoss	-170000000	usd
	us-gaap	Profit Loss ProfitLoss	-564000000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	960000000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	935000000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	41000000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	51000000	usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	6000000	usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	54000000	usd
	bhc	Goodwill Impairment Loss Not Included In Asset Impairment Charges GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges	0	usd
	bhc	Goodwill Impairment Loss Not Included In Asset Impairment Charges GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges	402000000	usd
	bhc	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset Cash BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash	19000000	usd
	bhc	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset Cash BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash	40000000	usd
	bhc	Allowances For Losses On Accounts Receivable And Inventories AllowancesForLossesOnAccountsReceivableAndInventories	43000000	usd
	bhc	Allowances For Losses On Accounts Receivable And Inventories AllowancesForLossesOnAccountsReceivableAndInventories	43000000	usd
	bhc	Deferred Income Tax Noncash Expense Benefit DeferredIncomeTaxNoncashExpenseBenefit	-104000000	usd
	bhc	Deferred Income Tax Noncash Expense Benefit DeferredIncomeTaxNoncashExpenseBenefit	-33000000	usd
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	10000000	usd
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	4000000	usd
	bhc	Gain Loss Related To Litigation Settlement Gross GainLossRelatedToLitigationSettlementGross	-215000000	usd
	bhc	Gain Loss Related To Litigation Settlement Gross GainLossRelatedToLitigationSettlementGross	-24000000	usd
	us-gaap	Payments For Legal Settlements PaymentsForLegalSettlements	222000000	usd
	us-gaap	Payments For Legal Settlements PaymentsForLegalSettlements	3000000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	107000000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	103000000	usd
	bhc	Amortization Interim Contract And Inventory Step From Acquisition AmortizationInterimContractAndInventoryStepFromAcquisition	61000000	usd
	bhc	Amortization Interim Contract And Inventory Step From Acquisition AmortizationInterimContractAndInventoryStepFromAcquisition	0	usd
	bhc	Foreign Currency Transaction And Other Gain Loss Before Tax ForeignCurrencyTransactionAndOtherGainLossBeforeTax	33000000	usd
	bhc	Foreign Currency Transaction And Other Gain Loss Before Tax ForeignCurrencyTransactionAndOtherGainLossBeforeTax	-22000000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	112000000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	176000000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	218000000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	222000000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-120000000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	75000000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	333000000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	61000000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	996000000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	642000000	usd
	bhc	Payments To Acquire Businesses And For Other Investments PaymentsToAcquireBusinessesAndForOtherInvestments	45000000	usd
	bhc	Payments To Acquire Businesses And For Other Investments PaymentsToAcquireBusinessesAndForOtherInvestments	1887000000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	231000000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	117000000	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	2000000	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	11000000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	7000000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	13000000	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	11000000	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	13000000	usd
	us-gaap	Proceeds From Divestiture Of Businesses Net Of Cash Divested ProceedsFromDivestitureOfBusinessesNetOfCashDivested	7000000	usd
	us-gaap	Proceeds From Divestiture Of Businesses Net Of Cash Divested ProceedsFromDivestitureOfBusinessesNetOfCashDivested	5000000	usd
	us-gaap	Payments For Proceeds From Hedge Investing Activities PaymentsForProceedsFromHedgeInvestingActivities	-13000000	usd
	us-gaap	Payments For Proceeds From Hedge Investing Activities PaymentsForProceedsFromHedgeInvestingActivities	-13000000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-254000000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1997000000	usd
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	155000000	usd
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	3145000000	usd
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	1049000000	usd
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	1507000000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-212000000	usd
CY2024Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent	31000000	usd
	us-gaap	Nature Of Operations NatureOfOperations	<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">DESCRIPTION OF BUSINESS </span><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bausch Health Companies Inc. (the “Company” or “Bausch Health”) is a global, diversified specialty pharmaceutical and medical device company that develops, manufactures and markets, primarily in the therapeutic areas of gastroenterology (“GI”), hepatology, neurology and dermatology, a broad range of branded, generic and branded generic pharmaceuticals, over-the-counter (“OTC”) products and aesthetic medical devices, and, through its approximately 88% ownership of Bausch + Lomb Corporation (“Bausch + Lomb” or “B+L”), branded, and branded generic pharmaceuticals, OTC products and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment) in the therapeutic areas of eye health. The Company’s products are marketed directly or indirectly in approximately 90 countries.</span></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In preparing the unaudited Condensed Consolidated Financial Statements, management is required to make estimates and assumptions. The estimates and assumptions used by the Company affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the unaudited Condensed Consolidated Financial Statements, and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from these estimates and the differences could be material. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an ongoing basis, management reviews its estimates to ensure that these estimates appropriately reflect changes in the Company’s business and new information as it becomes available. If historical experience and other factors used by </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">management to make these estimates do not reasonably reflect future activity, the Company’s results of operations and financial position could be materially impacted.</span></div>
CY2023Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	1939000000	usd
	us-gaap	Valuation Allowances And Reserves Charged To Other Accounts ValuationAllowancesAndReservesChargedToOtherAccounts	5005000000	usd
	us-gaap	Valuation Allowances And Reserves Deductions ValuationAllowancesAndReservesDeductions	4794000000	usd
CY2024Q3	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	2150000000	usd
CY2022Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	1910000000	usd
	us-gaap	Valuation Allowances And Reserves Charged To Other Accounts ValuationAllowancesAndReservesChargedToOtherAccounts	4335000000	usd
	us-gaap	Valuation Allowances And Reserves Deductions ValuationAllowancesAndReservesDeductions	4298000000	usd
CY2023Q3	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	1947000000	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	34000000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	33000000	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	2000000	usd
	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	3000000	usd
	us-gaap	Allowance For Doubtful Accounts Receivable Recoveries AllowanceForDoubtfulAccountsReceivableRecoveries	0	usd
	bhc	Accounts Receivable Allowance For Foreign Exchange And Other AccountsReceivableAllowanceForForeignExchangeAndOther	3000000	usd
CY2024Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	30000000	usd
	bhc	Highly Liquid Investments Maturity Period HighlyLiquidInvestmentsMaturityPeriod	P3M
CY2023Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	292000000	usd
CY2022Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	241000000	usd
	bhc	Fair Value Recurring Basis Unobservable Input Reconciliation Liability Gain Loss Statement Of Income Extensible List Not Disclosed Flag FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag	Acquisition-related contingent consideration
	bhc	Fair Value Recurring Basis Unobservable Input Reconciliation Liability Gain Loss Statement Of Income Extensible List Not Disclosed Flag FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag	Acquisition-related contingent consideration
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	19000000	usd
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	40000000	usd
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Purchases FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases	1000000	usd
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Purchases FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases	39000000	usd
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements	27000000	usd
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements	22000000	usd
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Other Comprehensive Income FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome	0	usd
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Other Comprehensive Income FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome	1000000	usd
CY2024Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	285000000	usd
CY2023Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	299000000	usd
CY2024Q3	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	37000000	usd
CY2023Q3	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	52000000	usd
CY2024Q3	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	248000000	usd
CY2023Q3	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	247000000	usd
CY2024Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	538000000	usd
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	509000000	usd
CY2024Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	108000000	usd
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	124000000	usd
CY2024Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1009000000	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	911000000	usd
CY2024Q3	us-gaap	Inventory Gross InventoryGross	1655000000	usd
CY2023Q4	us-gaap	Inventory Gross InventoryGross	1544000000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	27119000000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	23170000000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3949000000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	27262000000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	22509000000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	4753000000	usd
CY2024Q3	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	28822000000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	23170000000	usd
CY2024Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	5652000000	usd
CY2023Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	28965000000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	22509000000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	6456000000	usd
CY2024Q3	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	6000000	usd
CY2023Q3	us-gaap	Asset Impairment Charges AssetImpairmentCharges	4000000	usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	54000000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	261000000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	993000000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	871000000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	833000000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	235000000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	216000000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	540000000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3949000000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	11547000000	usd
CY2023	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	31000000	usd
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	493000000	usd
CY2023	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-98000000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	11183000000	usd
	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	2000000	usd
	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	14000000	usd
CY2024Q3	us-gaap	Goodwill Goodwill	11171000000	usd
CY2024Q3	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	5497000000	usd
CY2024Q3	bhc	Accrued Product Rebate Current AccruedProductRebateCurrent	1305000000	usd
CY2023Q4	bhc	Accrued Product Rebate Current AccruedProductRebateCurrent	1069000000	usd
CY2024Q3	bhc	Accrued Product Return Current AccruedProductReturnCurrent	373000000	usd
CY2023Q4	bhc	Accrued Product Return Current AccruedProductReturnCurrent	380000000	usd
CY2024Q3	bhc	Legalsettlementsandrelatedfees Legalsettlementsandrelatedfees	337000000	usd
CY2023Q4	bhc	Legalsettlementsandrelatedfees Legalsettlementsandrelatedfees	344000000	usd
CY2024Q3	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	318000000	usd
CY2023Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	360000000	usd
CY2024Q3	us-gaap	Interest Payable Current InterestPayableCurrent	237000000	usd
CY2023Q4	us-gaap	Interest Payable Current InterestPayableCurrent	236000000	usd
CY2024Q3	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	102000000	usd
CY2023Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	47000000	usd
CY2024Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	714000000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	697000000	usd
CY2024Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3386000000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3133000000	usd
CY2024Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	20359000000	usd
CY2024Q3	us-gaap	Long Term Debt LongTermDebt	21507000000	usd
CY2023Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	21006000000	usd
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	22388000000	usd
CY2024Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	453000000	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	450000000	usd
CY2024Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	21054000000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	21938000000	usd
CY2024Q3	us-gaap	Debt Weighted Average Interest Rate DebtWeightedAverageInterestRate	0.0788
CY2023Q4	us-gaap	Debt Weighted Average Interest Rate DebtWeightedAverageInterestRate	0.0805
CY2024Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	39000000	usd
CY2024Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	2370000000	usd
CY2024Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	757000000	usd
CY2024Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	6823000000	usd
CY2024Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	7168000000	usd
CY2024Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	1609000000	usd
CY2024Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal After Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive	1593000000	usd
CY2024Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	20359000000	usd
CY2024Q3	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	-1148000000	usd
CY2024Q3	us-gaap	Long Term Debt LongTermDebt	21507000000	usd
CY2024Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	38000000	usd
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	29000000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	107000000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	103000000	usd
CY2024Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	38000000	usd
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	29000000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	107000000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	103000000	usd
CY2024Q3	bhc	Research And Development Expense Product Related ResearchAndDevelopmentExpenseProductRelated	141000000	usd
CY2023Q3	bhc	Research And Development Expense Product Related ResearchAndDevelopmentExpenseProductRelated	146000000	usd
	bhc	Research And Development Expense Product Related ResearchAndDevelopmentExpenseProductRelated	440000000	usd
	bhc	Research And Development Expense Product Related ResearchAndDevelopmentExpenseProductRelated	430000000	usd
CY2024Q3	bhc	Research And Development Expense Quality Assurance ResearchAndDevelopmentExpenseQualityAssurance	5000000	usd
CY2023Q3	bhc	Research And Development Expense Quality Assurance ResearchAndDevelopmentExpenseQualityAssurance	7000000	usd
	bhc	Research And Development Expense Quality Assurance ResearchAndDevelopmentExpenseQualityAssurance	13000000	usd
	bhc	Research And Development Expense Quality Assurance ResearchAndDevelopmentExpenseQualityAssurance	22000000	usd
CY2024Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	146000000	usd
CY2023Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	153000000	usd
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	453000000	usd
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	452000000	usd
CY2024Q3	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	-188000000	usd
CY2023Q3	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	-24000000	usd
	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	-215000000	usd
	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	55000000	usd
CY2024Q3	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	25000000	usd
CY2023Q3	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	26000000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	19000000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	40000000	usd
CY2024Q3	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	5000000	usd
CY2023Q3	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	5000000	usd
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	10000000	usd
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	4000000	usd
CY2024Q3	bhc	In Process Research And Development Expense InProcessResearchAndDevelopmentExpense	15000000	usd
CY2023Q3	bhc	In Process Research And Development Expense InProcessResearchAndDevelopmentExpense	0	usd
	bhc	In Process Research And Development Expense InProcessResearchAndDevelopmentExpense	18000000	usd
	bhc	In Process Research And Development Expense InProcessResearchAndDevelopmentExpense	0	usd
CY2024Q3	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	2000000	usd
CY2023Q3	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	15000000	usd
	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	3000000	usd
	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	18000000	usd
CY2024Q3	bhc	Other Income Expense Net OtherIncomeExpenseNet	0	usd
CY2023Q3	bhc	Other Income Expense Net OtherIncomeExpenseNet	0	usd
	bhc	Other Income Expense Net OtherIncomeExpenseNet	0	usd
	bhc	Other Income Expense Net OtherIncomeExpenseNet	1000000	usd
CY2024Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-225000000	usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-60000000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-245000000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	128000000	usd
	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	132000000	usd
	bhc	Effective Income Tax Rate Reconciliation Discrete Items Amount EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount	-5000000	usd
	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	-7000000	usd
	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	3000000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	181000000	usd
	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	90000000	usd
	bhc	Effective Income Tax Rate Reconciliation Discrete Items Amount EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount	91000000	usd
	us-gaap	Income Tax Reconciliation Tax Settlements IncomeTaxReconciliationTaxSettlements	41000000	usd
	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	27000000	usd
	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	18000000	usd
	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	7000000	usd
CY2024Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	2493000000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	2254000000	usd
CY2024Q3	bhc	Unrecognized Tax Benefits Including Interest And Penalties UnrecognizedTaxBenefitsIncludingInterestAndPenalties	947000000	usd
CY2023Q4	bhc	Unrecognized Tax Benefits Including Interest And Penalties UnrecognizedTaxBenefitsIncludingInterestAndPenalties	918000000	usd
CY2024Q3	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	61000000	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	51000000	usd
CY2024Q3	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	410000000	usd
CY2024Q3	us-gaap	Decrease In Unrecognized Tax Benefits Is Reasonably Possible DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible	29000000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-85000000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-378000000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-139000000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-553000000	usd
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	368400000	shares
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	368400000	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	365400000	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	365400000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	367700000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	367700000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	364500000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	364500000	shares
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.23
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.23
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.03
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.03
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.38
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.38
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.52
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.52
CY2024Q3	bhc	Legalsettlementsandrelatedfees Legalsettlementsandrelatedfees	337000000	usd
CY2024Q3	bhc	Amortization Of Intangible Assets Excluding Amortization Allocated To Revenues Cost Of Good Sold AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold	274000000	usd
CY2023Q3	bhc	Amortization Of Intangible Assets Excluding Amortization Allocated To Revenues Cost Of Good Sold AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold	253000000	usd
	bhc	Amortization Of Intangible Assets Excluding Amortization Allocated To Revenues Cost Of Good Sold AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold	818000000	usd
	bhc	Amortization Of Intangible Assets Excluding Amortization Allocated To Revenues Cost Of Good Sold AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold	795000000	usd
CY2024Q3	bhc	Goodwill Impairment Loss Not Included In Asset Impairment Charges GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges	0	usd
CY2023Q3	bhc	Goodwill Impairment Loss Not Included In Asset Impairment Charges GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges	402000000	usd
	bhc	Goodwill Impairment Loss Not Included In Asset Impairment Charges GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges	0	usd
	bhc	Goodwill Impairment Loss Not Included In Asset Impairment Charges GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges	402000000	usd
CY2024Q3	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2023Q3	us-gaap	Asset Impairment Charges AssetImpairmentCharges	4000000	usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	6000000	usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	54000000	usd
CY2024Q3	bhc	Restructuring Charges And Initial Public Offering Costs RestructuringChargesAndInitialPublicOfferingCosts	1000000	usd
CY2023Q3	bhc	Restructuring Charges And Initial Public Offering Costs RestructuringChargesAndInitialPublicOfferingCosts	14000000	usd
	bhc	Restructuring Charges And Initial Public Offering Costs RestructuringChargesAndInitialPublicOfferingCosts	25000000	usd
	bhc	Restructuring Charges And Initial Public Offering Costs RestructuringChargesAndInitialPublicOfferingCosts	40000000	usd
CY2024Q3	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-225000000	usd
CY2023Q3	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-60000000	usd
	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-245000000	usd
	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	0	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	318000000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	14000000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	988000000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	601000000	usd
CY2024Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	7000000	usd
CY2023Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	6000000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	24000000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	19000000	usd
CY2024Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	346000000	usd
CY2023Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	339000000	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	1051000000	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	965000000	usd
CY2024Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2023Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	23000000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2024Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	0	usd
CY2023Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-7000000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-26000000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-38000000	usd
CY2024Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-21000000	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-326000000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-42000000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-383000000	usd
CY2024Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2510000000	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2238000000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7066000000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	6349000000	usd
	bhc	Concentration Risk Number Of Products ConcentrationRiskNumberOfProducts	10	product
	bhc	Concentration Risk Number Of Products ConcentrationRiskNumberOfProducts	10	product
CY2024Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2510000000	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2238000000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7066000000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	6349000000	usd

Files In Submission

Name	View Source	Status
bhc-20240930_cal.xml	Edgar Link	unprocessable
0000885590-24-000036-index-headers.html	Edgar Link	pending
0000885590-24-000036-index.html	Edgar Link	pending
0000885590-24-000036.txt	Edgar Link	pending
0000885590-24-000036-xbrl.zip	Edgar Link	pending
bhc-20240930.htm	Edgar Link	pending
bhc-20240930.xsd	Edgar Link	pending
exhibit101q32024.htm	Edgar Link	pending
exhibit102q32024.htm	Edgar Link	pending
exhibit311q32024.htm	Edgar Link	pending
exhibit312q32024.htm	Edgar Link	pending
exhibit321q32024.htm	Edgar Link	pending
exhibit322q32024.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_0a.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
bhc-20240930_def.xml	Edgar Link	unprocessable
bhc-20240930_lab.xml	Edgar Link	unprocessable
bhc-20240930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
bhc-20240930_htm.xml	Edgar Link	completed
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BHC
Bausch Health Companies Inc. Stock $bhc

2024 Q4 Form 10-Q Financial Statement

#000088559024000036 Filed on October 31, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BHC Bausch Health Companies Inc. Stock $bhc

2024 Q4 Form 10-Q Financial Statement

#000088559024000036 Filed on October 31, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BHC
Bausch Health Companies Inc. Stock $bhc